{"title":"Thank you to The Lancet Gastroenterology & Hepatology's statistical and peer reviewers in 2024","authors":"","doi":"10.1016/s2468-1253(25)00020-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00020-2","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"78 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Inflammatory bowel disease in south Asia: a scoping review","authors":"Shabari Shenoy, Anuraag Jena, Carrie Levinson, Vishal Sharma, Parakkal Deepak, Tina Aswani-Omprakash, Shaji Sebastian, Jean-Frederic Colombel, Manasi Agrawal","doi":"10.1016/s2468-1253(24)00341-8","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00341-8","url":null,"abstract":"Inflammatory bowel disease (IBD) is rising at an alarming rate in south Asia and there is a paucity of data on IBD in this region. For this scoping review, we conducted a systematic search to identify all observational and interventional studies on IBD in south Asia. Of 14 924 potentially eligible studies, 524 were included in this scoping review and summarised under the domains of epidemiology, natural history, phenotype and comorbid conditions, therapeutics, and psychosocial health. According to the literature, IBD incidence and prevalence are rising in south Asia and among south Asian immigrants, and the diagnostic rate is higher in men than in women. Genetic predisposition is an important risk factor in south Asia, whereas environmental risk factors are less clear. Delay in diagnosis, although possibly decreasing over time, is common in south Asia and is associated with worse outcomes. There are no clear differences in IBD phenotype and severity in south Asia relative to Europe and North America. Corticosteroids and immunomodulators are the mainstay of treatment in south Asia whereas the use of biologics is less common. Mental health disorders, malnutrition, and reduced quality of life are prevalent in patients with IBD in south Asia, and the use of complementary and alternative medicines among patients is an important consideration. Key knowledge gaps include the paucity of data from countries other than India, prospective, long-term, follow-up studies, and clinical drug trials in south Asia. IBD is a growing challenge in this region and warrants urgent clinical interventions, research, resource allocation, and health policy implementation.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"87 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Alcohol and cancer risk: bridging the awareness gap","authors":"","doi":"10.1016/s2468-1253(25)00014-7","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00014-7","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"183 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew Nguyen, Christopher F D Li Wai Suen, Ashish Srinivasan, Jonathan Segal, Abhinav Vasudevan
{"title":"Vedolizumab for prevention of recurrence of Crohn's disease","authors":"Andrew Nguyen, Christopher F D Li Wai Suen, Ashish Srinivasan, Jonathan Segal, Abhinav Vasudevan","doi":"10.1016/s2468-1253(24)00435-7","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00435-7","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"130 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to Lancet Gastroenterol Hepatol 2023; 8: 976–89","authors":"","doi":"10.1016/s2468-1253(25)00003-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00003-2","url":null,"abstract":"<em>Vermeire S, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.</em> Lancet Gastroenterol Hepatol <em>2023; <strong>8:</strong> 976–89</em>—In this Article, the declaration of interest statement for PDRH should read: “PDRH has received grants from AbbVie, the Crohn's & Colitis Foundation, the National Institutes of Health, and Takeda; and has served as a consultant for AbbVie, Eli Lilly, the Gastrointestinal Health Foundation, Imedex, Pfizer, Takeda, and Vindico Medical Education.” This correction has been made to the online version as of Feb 12, 2025.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"15 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hailemichael Desalegn, Lasse Rossvoll, Fufa Hunduma, Nega Berhe, Asgeir Johannessen
{"title":"Hepatitis B treatment in Africa: learning points from a scale-up programme in Ethiopia","authors":"Hailemichael Desalegn, Lasse Rossvoll, Fufa Hunduma, Nega Berhe, Asgeir Johannessen","doi":"10.1016/s2468-1253(24)00396-0","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00396-0","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"59 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research in Brief","authors":"Holly Baker","doi":"10.1016/s2468-1253(25)00021-4","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00021-4","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>TACE and immunotherapies for hepatocellular carcinoma</h2>Two phase 3 trials—EMERALD-1 and LEAP-012—highlight promising advances in the treatment of unresectable hepatocellular carcinoma with transarterial chemoembolisation (TACE) combined with immunotherapeutic agents.In EMERALD-1, Bruno Sangro and colleagues randomly assigned patients with unresectable hepatocellular carcinoma amenable to embolisation to receive TACE (current standard of care) plus either durvalumab plus bevacizumab (n=204), durvalumab plus placebo (n=207), or placebo alone (n=205).</section></section><section><section><h2>Thermal ablation for small colorectal liver metastases</h2>Thermal ablation is as efficacious as surgical resection for treating small colorectal liver metastases, but with fewer complications, according to the COLLISION phase 3 trial.Susan van der Lei and colleagues randomly assigned patients with ten or fewer small-size (≤3 cm) colorectal liver metastases to receive either thermal ablation (n=148) or surgical resection (n=148). The study was stopped early at a preplanned interim analysis, after a median follow-up of 28·9 months, based on a</section></section><section><section><h2>Perioperative chemotherapy for oesophageal cancer</h2>Perioperative chemotherapy improves survival in patients with resectable oesophageal adenocarcinoma, according to the ESOPEC phase 3 trial.Jens Hoeppner and colleagues randomly assigned patients to receive either perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery (n=221) or preoperative chemoradiotherapy (radiotherapy at 41·4 Gy and carboplatin and paclitaxel) plus surgery (n=217). At median follow-up of 55 months, 3-year overall survival</section></section><section><section><h2>Plozasiran for persistent chylomicronaemia</h2>The siRNA plozasiran significantly lowers triglyceride levels and reduces the risk of pancreatitis in patients with persistent chylomicronaemia, suggests the PALISADE phase 3 trial.Gerald F Watts and colleagues randomly assigned patients to receive plozasiran at 25 mg (n=26) or 50 mg (n=24), or placebo (n=25), subcutaneously every 3 months for 12 months. At 10 months, the median percentage change from baseline in fasting triglyceride level was −80% in the plozasiran 25 mg group, −78% in the</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"2 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
